Business overview
 Business Outline
 Business Strategy
   PPI
   Platform Technology
   (INTENDD)
   VEGF inhibitor
   IL-6 inhibitor
   IgE inhibitor
   Notch1 inhibitor
   Tubulin polymerization
   inhibitor
   Zinc chelators
   CIRP
Top Site Map Contact Us Japanese

Copyright © Interprotein Corporation. All rights Reserved

Business Strategy
Strategy for drug discovery targeting zinc chelators for allergy treatment

Prof. Toshio Hirano, Osaka University and Deputy Director of Riken Research Center for Allergy and Immunology, first found that zinc ions are required for initiation of allergic response. Upon allergic stimulation, granules in mast cells and eosiophils migrate along the cyoskelton to the plasma membrane, and finally fuse to plasma membrane and release chemical mediators. Zinc ions are required for translocation of granules. We are developing therapeutics to suppress allergic response by depriving zinc ion from a diseased site. We believe that this should be effective for the treatment of diseases such as atopic dermatitis and allergic rhinitis.

inflammatory bowel
disease
bronchial asthma
allergic rhinitis
atopic dermatitis
allergic conjunctivitis